Newsfile Corp
28 Jun 2026, 12:13 UTC · 11w ago
Verdict
Headline leans bearish. We score ADMA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
ADMA Biologics is alleged to have used channel stuffing to report 20% revenue growth in 2025, while real growth was actually -3%.
So whatAllegations of systemic revenue inflation and artificial growth are fundamental red flags for valuation and management integrity.
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed against ADMA Biologics alleging false statements and lack of adequate internal controls.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 91% of claims this week
ADMA Biologics is accused of engaging in an undisclosed related party transaction.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+1.1%
Price is moving against the score
$8.85 vs $8.75 close before publication (Jun 26) · not market-adjusted
ADMA chart →
